Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,962.50    41.00 (2.13%)
Bid:
1,960.50
Ask:
1,962.00
Spread: 1.50 (0.077%)
Market Cap: £78.67b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

7 Oct 2022 16:38

RNS Number : 2349C
GSK PLC
07 October 2022
 

GSK plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

11

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

11

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

31

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I Whyte

b)

Position/status

PCA of Ms V Whyte (Company Secretary)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

1,046

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Connor

b)

Position/status

PCA of Mr R Connor (President, Global Vaccines)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

424

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFSWFIWEESEDS
Date   Source Headline
17th Apr 20237:00 amRNSGepotidacin positive phase III data
3rd Apr 20233:00 pmRNSTotal Voting Rights
28th Mar 20237:00 amRNSPositive phase III RUBY results for Jemperli
27th Mar 20231:00 pmRNSPublication of 2023 AGM Notice
24th Mar 20239:59 amRNSStatement: Zantac (ranitidine) litigation
21st Mar 20233:30 pmRNSDirector/PDMR Shareholding
20th Mar 20233:30 pmRNSDirector/PDMR Shareholding
14th Mar 20237:05 amRNSPositive phase III results for MenABCWY vaccine
14th Mar 20237:00 amRNSNucala NDA accepted for review in China
13th Mar 20233:30 pmRNSDirector/PDMR Shareholding
10th Mar 20234:26 pmRNSGSK Annual Report 2022 on Form 20-F
10th Mar 202310:36 amRNSGSK publishes Annual Report 2022
2nd Mar 20237:00 amRNSFDA Ad Com votes to support GSK RSV OA vaccine
1st Mar 20233:00 pmRNSTotal Voting Rights
27th Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSViiV Healthcare announces Cabenuva positive data
22nd Feb 20233:30 pmRNSDirector/PDMR Shareholding
16th Feb 20237:00 amRNSNEJM publishes GSK RSV OA vaccine candidate trial
15th Feb 20234:04 pmRNSDirector/PDMR Shareholding
15th Feb 20234:00 pmRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
13th Feb 20235:35 pmRNSEMTN Notes repurchase results
10th Feb 20233:30 pmRNSDirector/PDMR Shareholding
10th Feb 20237:05 amRNSJemperli full FDA approval following GARNET trial
10th Feb 20237:00 amRNSJemperli FDA ODAC positive outcome
2nd Feb 20237:00 amRNSDaprodustat approved by US FDA for anaemia of CKD
1st Feb 20233:30 pmRNSDirector/PDMR Shareholding
1st Feb 20233:00 pmRNSTotal Voting Rights
1st Feb 20237:05 amRNSBenlysta granted Orphan Drug Designation by US FDA
1st Feb 20237:00 amRNSFinal Results
18th Jan 20233:30 pmRNSDirector/PDMR Shareholding
17th Jan 20233:30 pmRNSDirector/PDMR Shareholding
16th Jan 20233:30 pmRNSDirector/PDMR Shareholding
13th Jan 20233:30 pmRNSDirector/PDMR Shareholding
12th Jan 20233:30 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:00 pmRNSTotal Voting Rights
22nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
21st Dec 20223:35 pmRNSDirector/PDMR Shareholding
21st Dec 20223:30 pmRNSDirector/PDMR Shareholding
15th Dec 20223:30 pmRNSBoard and Committee Changes
13th Dec 20223:30 pmRNSDirector/PDMR Shareholding
7th Dec 20227:00 amRNSStatement: Zantac (ranitidine) litigation
5th Dec 20224:00 pmRNSTransfer of Treasury Shares
2nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20227:00 amRNSEMA file accepted for momelotinib
2nd Dec 20227:00 amRNSJemperli positive trial in endometrial cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.